Connect Biopharma Holdings (CNTB) Current Deferred Revenue (2023 - 2025)
Historic Current Deferred Revenue for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $165000.0.
- Connect Biopharma Holdings' Current Deferred Revenue changed N/A to $165000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $165000.0, marking a year-over-year change of. This contributed to the annual value of $164000.0 for FY2024, which is 9876.88% down from last year.
- As of Q3 2025, Connect Biopharma Holdings' Current Deferred Revenue stood at $165000.0.
- In the past 5 years, Connect Biopharma Holdings' Current Deferred Revenue registered a high of $13.3 million during Q4 2023, and its lowest value of $162000.0 during Q2 2023.
- Over the past 3 years, Connect Biopharma Holdings' median Current Deferred Revenue value was $164000.0 (recorded in 2024), while the average stood at $2.4 million.
- Within the past 5 years, the most significant YoY rise in Connect Biopharma Holdings' Current Deferred Revenue was 9876.88% (2024), while the steepest drop was 9876.88% (2024).
- Over the past 3 years, Connect Biopharma Holdings' Current Deferred Revenue (Quarter) stood at $13.3 million in 2023, then tumbled by 98.77% to $164000.0 in 2024, then rose by 0.61% to $165000.0 in 2025.
- Its last three reported values are $165000.0 in Q3 2025, $164000.0 for Q2 2025, and $164000.0 during Q1 2025.